CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 53 enrolled
Drug / intervention
Pathwaysbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04161157
NCT04161157N/ACompleted
CompareCT.gov

Piloting Pathways, a Hope-enhancing Intervention to Address Activity and Role Function in Metastatic Lung Cancer Patients

Laurie McLouth·interventional·Posted Nov 13, 2019·Updated Oct 5, 2023

In Brief

A clinical study evaluating Pathways for Metastatic Lung Cancer. Completed, enrolled 53 participants across 1 site.

Detailed Summary

The purpose of this research is to determine the feasibility of a new supportive intervention, called Pathways, for patients with advanced stage and metastatic lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Lung Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedNov 13, 2019
Enrollment StartJan 13, 2020
Primary CompletionAug 3, 2022
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 6.6 years ago

Interventions

Pathwaysbehavioral

Goal-setting intervention to help patients identify personal values, value-consistent goals, and ways to pursue goals and address goal obstacles. Although potential refinements may occur based on aim 1 (refining procedures and content with 6 patients), Pathways is designed to consist primarily of 2 in-person sessions (\~30-60 minutes) delivered when patients are in clinic for cancer treatment, with supporting phone calls and contact in between sessions.